Beta-blockers linked to reduced mortality in HFrEF, A-fib

β-blockers linked to reduced mortality in HFrEF, A-fib

(HealthDay)—β-blockers are associated with significantly reduced mortality, but not hospitalizations, in patients with heart failure and reduced ejection fraction (HFrEF) and atrial fibrillation (AF), according to a study published online Jan. 11 in JACC: Heart Failure.

Julia Cadrin-Tourigny, M.D., from the Université de Montréal, and colleagues examined the impact of β-blockers on mortality and hospitalizations in patients with AF and HFrEF in the AF-CHF trial. Among 1,376 subjects randomized in the trial, the authors propensity-matched those without β-blockers at baseline to a maximum of two exposed patients.

The researchers found that β-blockers correlated with significantly lower all-cause mortality (hazard ratio [HR], 0.721; 95 percent confidence interval [CI], 0.549 to 0.945; P = 0.0180) but not hospitalizations (HR, 0.886; 95 percent CI, 0.715 to 1.100; P = 0.2232) during a median follow-up of 37 months. In sensitivity analyses that modeled β-blockers as a time-dependent variable the results were similar (HR for all-cause mortality, 0.668; 95 percent CI, 0.511 to 0.874; P = 0.0032; HR for hospitalizations, 0.814; 95 percent CI, 0.653 to 1.014; P = 0.0658). With respect to and hospitalizations, there were no significant interactions for β-blockers and pattern or burden of AF.

"These results support current evidence-based recommendations for β-blockers in with HFrEF, whether or not they have associated AF," the authors write.


Explore further

Beta-blockers don't improve heart failure, A-fib outcomes

More information: Full Text

Copyright © 2017 HealthDay. All rights reserved.

Citation: Beta-blockers linked to reduced mortality in HFrEF, A-fib (2017, January 12) retrieved 18 September 2019 from https://medicalxpress.com/news/2017-01-blockers-linked-mortality-hfref-a-fib.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
0 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more